MGTX
NEUTRAL
$9.63
Live
MeiraGTx Holdings plc · NASDAQ
Target $26.0
(+170.0%)
$4.55
52W Range
$9.88
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$784.33M
P/E
N/A
ROE
-368.2%
Profit margin
-140.3%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
MGTX presents a stark dichotomy between catastrophic financial health and explosive growth. The deterministic baseline is severely weak, highlighted by a Piotroski F-Score of 1/9 and a negative Price-to-Book ratio, indicating significant insolvency risk and poor operational efficiency. However, the company is experiencing massive revenue growth (252% YoY) and has strong analyst backing with a $26 target price. The investment profile is purely speculative, relying on future commercial success to offset current balance sheet distress.
Key Strengths
Exceptional revenue growth of 252.30% YoY
Very high gross margins (94.05%) typical of high-value biotech
Strong analyst consensus with a 'strong_buy' recommendation
Significant upside potential relative to analyst target price ($26.00)
Positive operating margin (35.13%) suggesting core business scalability
Key Risks
Critical financial health indicated by Piotroski F-Score of 1/9
Liquidity risk with a current ratio of 0.75 (below 1.0)
Negative equity as evidenced by a Price/Book of -135.63
Bearish insider sentiment with sales from the CEO and COO
Deeply negative profit margins (-140.31%)
AI Fair Value Estimate
Based on comprehensive analysis
$15.5
+61.0% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
29
Weak
20
85
30
10
0
AI Verdict
Speculative Growth
Key drivers: Hyper-growth in revenue, Severe balance sheet deterioration, High analyst optimism
Confidence
85%
Value
20/100
Trades at a significant premium to book value (which is negative) and lacks traditional valuation anchors.
Positives
- High growth may justify current premium
Watchpoints
- Negative P/B ratio
- High P/S ratio of 9.64
- No Graham Number available due to negative earnings
Future
85/100
Growth metrics are the primary driver of the stock's current valuation.
Positives
- 252% YoY revenue growth
- Recent EPS surprise of +130.7%
- Strong analyst price targets
Watchpoints
- Dependence on continued funding or rapid profitability
Past
30/100
Historical earnings track record is poor, though recent quarters show improvement.
Positives
- Recent 1-year price appreciation of 75.7%
Watchpoints
- Consistent history of earnings misses
- Long-term 5Y change is negative (-29.7%)
Health
10/100
Deterministic health scores indicate a company in financial distress.
Positives
- Positive operating margin
Watchpoints
- Piotroski F-Score of 1/9
- Current ratio < 1.0
- Negative ROE of -368.19%
Dividend
0/100
Non-dividend paying growth company.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$9.63
Analyst Target
$26.0
Upside/Downside
+170.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MGTX and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MGTX
MeiraGTx Holdings plc
Primary
|
-29.7% | +81.4% | +75.7% | +23.0% | +30.3% | +1.2% |
|
ARVN
Arvinas, Inc.
Peer
|
-84.3% | -57.8% | +42.5% | +57.4% | -7.0% | -10.4% |
|
AMN
AMN Healthcare Services, Inc.
Peer
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
|
IART
Integra LifeSciences Holdings Corporation
Peer
|
-85.7% | -83.0% | -43.2% | -25.8% | +3.0% | +3.9% |
|
KURA
Kura Oncology, Inc.
Peer
|
-69.7% | -27.5% | +54.0% | -12.0% | -6.0% | +0.7% |
MGT
MeiraGTx Holdings plc
Primary
5Y
-29.7%
3Y
+81.4%
1Y
+75.7%
6M
+23.0%
1M
+30.3%
1W
+1.2%
ARV
Arvinas, Inc.
Peer
5Y
-84.3%
3Y
-57.8%
1Y
+42.5%
6M
+57.4%
1M
-7.0%
1W
-10.4%
AMN
AMN Healthcare Services, Inc.
Peer
5Y
-72.8%
3Y
-78.8%
1Y
-26.3%
6M
+3.5%
1M
+28.0%
1W
+7.7%
IAR
Integra LifeSciences Holdings Corporation
Peer
5Y
-85.7%
3Y
-83.0%
1Y
-43.2%
6M
-25.8%
1M
+3.0%
1W
+3.9%
KUR
Kura Oncology, Inc.
Peer
5Y
-69.7%
3Y
-27.5%
1Y
+54.0%
6M
-12.0%
1M
-6.0%
1W
+0.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-14.48
PEG Ratio
N/A
P/B Ratio
-135.63
P/S Ratio
9.64
EV/Revenue
9.92
EV/EBITDA
-8.64
Market Cap
$784.33M
Profitability
Profit margins and return metrics
Profit Margin
-140.31%
Operating Margin
35.13%
Gross Margin
94.05%
ROE
-368.19%
ROA
-25.76%
Growth
Revenue and earnings growth rates
Revenue Growth
+252.3%
Earnings Growth
N/A
Q/Q Revenue Growth
+252.33%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.75
Weak
Quick Ratio
0.69
Poor
Cash/Share
$0.81
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
99.4%
Op. Margin
35.1%
Net Margin
20.0%
Total Assets
$0.2B
Liabilities
$0.3B
Equity
$-0.0B
Debt/Equity
-43.19x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
99%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-12
$N/A
2026-03-26
$0.19
+130.7% surprise
2025-11-13
$-0.62
-26.5% surprise
2025-08-14
$-0.48
-2.7% surprise
Healthcare Sector Comparison
Comparing MGTX against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-368.19%
This Stock
vs
-86.0%
Sector Avg
+328.1%
(Excellent)
Profit Margin
-140.31%
This Stock
vs
-11.76%
Sector Avg
+1093.2%
(Superior)
Revenue Growth
252.3%
This Stock
vs
90.15%
Sector Avg
+179.9%
(Fast Growth)
Current Ratio
0.75
This Stock
vs
3.67
Sector Avg
-79.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MGTX
MeiraGTx Holdings plc
|
NEUTRAL | $784.33M | - | -368.2% | -140.3% | $9.63 | |
|
ARVN
Arvinas, Inc.
|
BEARISH | $782.25M | - | -16.2% | -30.8% | $12.18 | Compare |
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 | Compare |
|
IART
Integra LifeSciences...
|
NEUTRAL | $771.58M | - | -39.9% | -31.6% | $9.9 | Compare |
|
KURA
Kura Oncology, Inc.
|
BEARISH | $765.82M | - | -94.8% | -% | $8.67 | Compare |
MGTX
MeiraGTx Holdings plc
NEUTRAL
Mkt Cap
$784M
P/E
-
ROE
-368.2%
Price
$9.63
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-07 | NAYLOR STUART | Officer | Sale | 27,661 | $258,907 |
| 2026-03-24 | FORBES ALEXANDRIA | Chief Executive Officer | Sale | 62,000 | $459,420 |
| 2026-02-20 | FORBES ALEXANDRIA | Chief Executive Officer | Stock Award | 62,500 | - |
| 2026-02-20 | ZELDIN ROBERT K | Officer | Stock Award | 7,500 | - |
| 2026-02-20 | GIROUX RICHARD | Chief Operating Officer | Stock Award | 60,000 | - |
| 2026-02-20 | NAYLOR STUART | Officer | Stock Award | 25,000 | - |
| 2026-02-20 | WOLLIN ROBERT J | General Counsel | Stock Award | 11,250 | - |
| 2026-01-16 | FORBES ALEXANDRIA | Chief Executive Officer | Stock Award | 310,000 | - |
| 2026-01-16 | ZELDIN ROBERT K | Officer | Stock Award | 35,000 | - |
| 2026-01-16 | GIROUX RICHARD | Chief Operating Officer | Stock Award | 310,000 | - |
| 2026-01-16 | NAYLOR STUART | Officer | Stock Award | 75,000 | - |
| 2026-01-16 | WOLLIN ROBERT J | General Counsel | Stock Award | 50,000 | - |
| 2026-01-07 | FORBES ALEXANDRIA | Chief Executive Officer | Stock Award | 62,500 | - |
| 2026-01-07 | ZELDIN ROBERT K | Officer | Stock Award | 17,500 | - |
| 2026-01-07 | GIROUX RICHARD | Chief Operating Officer | Stock Award | 52,500 | - |
NAYLOR STUART
Officer
2026-04-07
27,661 shares
·
$258,907
FORBES ALEXANDRIA
Chief Executive Officer
2026-03-24
62,000 shares
·
$459,420
FORBES ALEXANDRIA
Chief Executive Officer
2026-02-20
62,500 shares
ZELDIN ROBERT K
Officer
2026-02-20
7,500 shares
GIROUX RICHARD
Chief Operating Officer
2026-02-20
60,000 shares
NAYLOR STUART
Officer
2026-02-20
25,000 shares
WOLLIN ROBERT J
General Counsel
2026-02-20
11,250 shares
FORBES ALEXANDRIA
Chief Executive Officer
2026-01-16
310,000 shares
ZELDIN ROBERT K
Officer
2026-01-16
35,000 shares
GIROUX RICHARD
Chief Operating Officer
2026-01-16
310,000 shares
NAYLOR STUART
Officer
2026-01-16
75,000 shares
WOLLIN ROBERT J
General Counsel
2026-01-16
50,000 shares
FORBES ALEXANDRIA
Chief Executive Officer
2026-01-07
62,500 shares
ZELDIN ROBERT K
Officer
2026-01-07
17,500 shares
GIROUX RICHARD
Chief Operating Officer
2026-01-07
52,500 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
8 analysts
Evercore ISI Group
2026-04-01
Outperform
Outperform
Piper Sandler
2026-03-27
Overweight
Overweight
B of A Securities
2026-03-27
Buy
Buy
Chardan Capital
2026-03-27
Buy
Buy
HC Wainwright & Co.
2025-11-24
Buy
RBC Capital
2025-11-14
Outperform
Outperform
Chardan Capital
2025-11-14
Buy
Buy
Piper Sandler
2025-11-11
Overweight
Overweight
Chardan Capital
2025-11-11
Buy
Buy
Raymond James
2025-10-21
Strong Buy
Past News Coverage
Recent headlines mentioning MGTX from our newsroom.
Newest → oldest
No matching news yet.